Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2013 | 03-2013 | 12-2012 | 12-2011 | |
| Sales | 75 | 75 | 0 | 0 |
| Gross Profit | 75 | 75 | N/A | N/A |
| Operating Expenses | 11,423 | 9,752 | 0 | 0 |
| Operating Income | -11,348 | -9,677 | N/A | N/A |
| Interest Expense | 490 | 12,624 | 0 | 0 |
| Other Income | 9 | 644 | 0 | 0 |
| Pre-tax Income | -11,829 | -21,657 | 0 | 0 |
| Net Income Continuous | -11,829 | -21,657 | N/A | N/A |
| Net Income | $-11,829 | $-21,657 | $N/A | $N/A |
| EPS Basic Total Ops | -75.25 | 25.54 | N/A | N/A |
| EPS Basic Continuous Ops | -56.52 | -106.05 | N/A | N/A |
| EPS Diluted Total Ops | -75.25 | 21.00 | N/A | N/A |
| EPS Diluted Continuous Ops | -56.52 | -34.07 | N/A | N/A |
| EBITDA(a) | $-10,828 | $-6,302 | $N/A | $N/A |